How many courses of treatment can Ibrutinib/Eco take to be effective?

Ibrutinib (Ibrutinib) is an oral targeted drug. Its mechanism of action is to irreversibly bind to BTK, thereby blocking the B cell receptor signaling pathway, thereby inhibiting the proliferation and survival of abnormal B cells. Compared with traditional chemotherapy, its mode of action is more unique. It does not rely on short-term cell killing, but gradually achieves the purpose of controlling the disease by continuously inhibiting tumor cell signaling. This also means that there are differences in the time it takes for ibrutinib to take effect in different patients.

Generally speaking, some patients may experience improvement in symptoms within a few weeks to1-2 months after taking the medication, such as reduced lymph node enlargement, reduction in night sweats, or recovery of physical strength. Especially in patients with chronic lymphocytic leukemia, the number of lymphocytes may temporarily increase in the early stage. This is actually a manifestation of the drug mobilizing tumor cells from lymph nodes or bone marrow into the blood circulation, and does not represent a worsening of the disease. As treatment continues, this indicator will gradually recover and stabilize.

For patients with mantle cell lymphoma or Waldenström's macroglobulinemia, the time for the efficacy to appear may be slightly different. Some patients need several months or even longer treatment before the tumor burden will be significantly reduced. Therefore, the efficacy evaluation of ibrutinib is usually based on 3-6 months as an observation point, and is comprehensively judged based on imaging and hematological indicators.

The treatment principle of ibrutinib is usually "continuous use" rather than a short-term course of treatment. In other words, it is more like a chronic disease medication for long-term management of the disease, and patients need to take it continuously under the guidance of a doctor until the disease progresses or the adverse events are tolerated. Different from periodic drug withdrawal like chemotherapy, ibrutinib emphasizes continuity to ensure that the BTK pathway is permanently inhibited and prevent tumor cells from reactivating.

Reference materials:https://www.imbruvica.com/